INNATE PHARMA : PETIT RAPPEL DES ETUDES IPH EN COURS (Nouvelle Etude MATISSE)

EL_CAMINO

26 mars 2023 •13:18

MONALIZUMAB (NKG2A):
-PACIFIC-9 (Phase 3) - NCT05221840 (AstraZeneca): Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients with Stage III NSCLC (Patients: 999) – EPCD May 2026 / ESCD May 2030
-NeoCOAST-2 (Phase 2) - NCT05061550 (AstraZeneca): Resectable early stage (II to IIIA) NSCLC (Patients: 350) – EPCD March 2026 / ESCD March 2026
-PIONeeR (Phase 2) - NCT03833440 (AP-HM): Advanced stage or recurrent NSCLC (Patients: 120) – EPCD October 2023 / ESCD February 2024
-UPSTREAM (Phase 2) - NCT03088059 (EORTC): Recurrent or Metastatic after first line platinum-based chemotherapy HNSCC (Patients: 340) – EPCD June 2025 / ESCD December 2025 – No more on the pipeline overview of website
LACUTAMAB (KIR3DL2)
-TELLOMAK (Phase 2) - NCT03902184 (Innate Pharma): R/R Sezary Syndrome and Stage IB-IV Mycosis Fungoides (Patients: 166) Cohort 1: R/R Sezary Syndrome – EPCD March 2023 / ESCD March 2024
-KILT (Phase 2) - NCT04984837 (LYSA): R/R Peripheral T Cell Lymphoma (Patients: 56) – EPCD January 2025 / ESCD January 2027
-XXX (Phase 1) – YYY (Innate Pharma) - Relapse/Refractory Peripheral T Cell Lymphoma (planned)
IPH5201-CD39 (Phase 2)
MATISSE (Phase 2) - NCT05742607 (AstraZeneca): Resectable Non-Small Cell Lung Cancer (Patients: 70) – EPCD June 2025 / ESCD September 2026
IPH5301-CD73 (Phase 1)
-XXX (Phase 1) - NCT05143970 (Innate Pharma): Anti-CD73 IPH5301 Alone or in Combination with Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) - Metastatic Breast, Pancreatic, Gastric, Lung, Ovary, Oesophageal, Endometrial cancer, Advanced Solid Tumor (Patients: 27) – EPCD July 2023 / ESCD July 2024
ANKET Platform:
IPH6101 (CD123/NKp46/CD16a)
-SAR443579 (Phase 1 / 2) - NCT05086315 (Sanofi): B-cell Acute Lymphoid Leukemia High Risk-Myelodisplasia (Patients: 82) – EPCD August 2025 / ESCD June 2026
IPH62 (B7-H3, tri-specific ANKET) with Sanofi
IPH6401 (BCMA, tri-specific ANKET) with Sanofi
IPH6501 (CD20, tetra-specific ANKET)

Disparus AVDORALIMAB (C5aR1), IPH25 and IPH26 (Siglec-9) – Co-development AZN – Pre-clinical et IPH43 (MICA/B ADC) – Co-development AZN – Pre-clinical